FY2027 Earnings Estimate for CRSP Issued By Zacks Research

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Zacks Research issued their FY2027 earnings estimates for CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($4.62) for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

A number of other research analysts also recently issued reports on the company. Barclays boosted their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target on the stock in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada decreased their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $43.31 on Wednesday. The stock has a 50-day simple moving average of $42.68 and a two-hundred day simple moving average of $45.82. The firm has a market capitalization of $3.71 billion, a PE ratio of -9.91 and a beta of 1.67. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $83.50.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its position in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the period. Capital International Investors increased its holdings in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after purchasing an additional 816,789 shares during the period. T. Rowe Price Investment Management Inc. raised its position in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. State Street Corp lifted its holdings in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the period. Finally, FMR LLC lifted its stake in CRISPR Therapeutics by 1.0% in the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after acquiring an additional 23,075 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Greene bought 7,000 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now owns 7,000 shares of the company’s stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.